Testing for Chlamydia Reinfection Among Adolescent Patients in Different Clinical Settings: How Are We Doing?

INTRODUCTION

Chlamydia trachomatis is the most frequently reported infectious disease in the United States, with high reinfection rates and highest prevalence among adolescents and young adults. National guidelines suggest testing for reinfection 3 months after chlamydia treatment, and 3 to 4 weeks after treatment during pregnancy. Our needs assessment evaluated retesting rates among adolescent and young adult patients across several clinical settings within one community.

METHODS

We performed retrospective chart reviews to examine chlamydia retest rates among 14 to 21-year-old patients treated for chlamydia within three different settings: an academic primary care site with family medicine and pediatrics clinics, an adolescent health center, and a group of school-based health centers (SBHCs). Per CDC guidelines, the goal treatment window was defined as retests conducted between 60 to 183 days after documented treatment for nonpregnant patients, and those conducted within 21 to 42 days posttreatment for pregnant patients.

RESULTS

Overall, 77/134 (57.5%) of patients were retested, with 59/143 (44%) retested within the goal time frame. Site rates of retesting within guideline timeframe were as follows: 38.5% at the academic family medicine site, 46.2% at the academic pediatrics site, 42.7% at the adolescent health center, and 55.0% at SBHCs. The reinfection rate among those appropriately retested was 22.0% (13/59). Of patients not retested appropriately, 25.3% had return visits at which they were not retested (a missed opportunity).

CONCLUSIONS

Our results indicate a need for interventions that encourage patients to return for retesting, and that trigger retesting during unrelated return visits.